Loading clinical trials...
Loading clinical trials...
A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (≥10 to <18 Years) With Type 2 Diabetes Mellitus
Conditions
Interventions
Canagliflozin 100 mg
Canagliflozin 300 mg
+1 more
Locations
106
United States
Arkansas Childrens Hospital
Little Rock, Arkansas, United States
Center of Excellence for Diabetes and Endocrinology (CEDE)
Sacramento, California, United States
American Institute of Research
Whittier, California, United States
University of Colorado School of Medicine/Children's Hospital Colorado
Aurora, Colorado, United States
Nemours DuPont Hospital for Children
Wilmington, Delaware, United States
TOPAZ Clinical Research
Apopka, Florida, United States
Start Date
July 21, 2017
Primary Completion Date
September 20, 2023
Completion Date
September 20, 2023
Last Updated
April 25, 2025
NCT06513026
NCT07112339
NCT06329375
NCT06945406
NCT06959901
NCT06574035
Lead Sponsor
Janssen Research & Development, LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions